Inhibition of RANK/RANKL signaling by denosumab induced an orchestrated antitumor immune response increasing CD8+ T-cell-mediated tumor cytotoxicity and decreasing neutrophil-mediated immunosuppression in breast cancer,393 which indicates that RANKL suppression may generate a synergistic therapeutic effect in primary and metastatic lesions. Here, TNFSF11 is linked to breast cancer.